Drug Profile


Alternative Names: 3,4-DAP; 3,4-DAP phosphate; 3,4-Diaminopyridine; Amifampridine phosphate; Firdapse; Zenas

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Assistance Publique Hopitaux de Paris
  • Developer BioMarin Pharmaceutical; Catalyst Pharmaceutical; Fondazione Istituto Neurologico Carlo Besta
  • Class Aminopyridines; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis; Lambert-Eaton myasthenic syndrome; Congenital myasthenic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lambert-Eaton myasthenic syndrome
  • Preregistration Congenital myasthenic syndromes
  • Phase II/III Myasthenia gravis

Most Recent Events

  • 17 Oct 2017 Catalyst Pharmaceuticals plans to initiate a phase III trial for Myasthenia gravis in USA (NCT03304054)
  • 30 Aug 2017 Catalyst Pharmaceutical Partners plans to conduct a pre-NDA meeting with US FDA for Lambert-Eaton myasthenic syndrome by January 2018
  • 30 Aug 2017 Catalyst Pharmaceutical Partners reaches agreement with US FDA on a Special Protocol Assessment (SPA) for a phase III trial for Myasthenia gravis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top